03:23 PM EST, 02/26/2025 (MT Newswires) -- Eli Lilly ( LLY ) on Wednesday outlined a plan to invest at least $27 billion to build four new pharmaceutical manufacturing sites in the US.

The pharmaceutical giant said that three of the planned facilities will manufacture active pharmaceutical ingredients, while the fourth will make injectable drugs. The company expects to announce the four site locations later this year, with production likely to commence within five years.

"Lilly's optimism about the potential of our pipeline across therapeutic areas -- cardiometabolic health, oncology, immunology and neuroscience -- drives our unprecedented commitment to our domestic manufacturing build-out," Chief Executive David Ricks said in a statement.

Lilly shares were up 1% in Wednesday late-afternoon trade. The stock has surged 18% so far in 2025.

The company expects to create more than 3,000 jobs for highly skilled workers at the planned sites. During site development, Lilly could create almost 10,000 construction jobs, it said.

"The Tax Cuts and Jobs Act legislation passed in 2017 during President (Donald) Trump's first term in office has been foundational to Lilly's domestic manufacturing investments, and it is essential that these policies are extended this year," Ricks said.

The company's capital expansion commitments in the US amounted to $23 billion from 2020 through 2024, according to the statement.

On Tuesday, Lilly launched higher doses of Zepbound, or tirzepatide, in single-dose vials and lowered the prices of two smaller doses of the weight-loss drug for self-pay patients. Also on Tuesday, Organovo ( ONVO ) said Lilly will acquire the former's FXR program, including its lead asset, FXR314, aimed at treating inflammatory bowel disease.

Earlier this month, Lilly posted in-line fourth-quarter sales, while reiterating a 2025 revenue guidance that implied the top line will grow at the same pace as it did last year.

Price: 912.34, Change: +10.54, Percent Change: +1.17